Ojala A, Nikkanen V N, Paloheimo S, Palojoki A, Thölix E
Strahlentherapie. 1983 Dec;159(12):775-7.
A controlled clinical trial was performed to test two different chemotherapy regimens (doxorubicin + cyclophosphamide + vincristine versus CCNU + vincristine) in 100 patients with metastatic or recurrent non-small cell bronchogenic carcinoma. There was no significant difference between treatment groups in survival or in response. Only 4 patients had a partial remission and there were no complete responders. Median survival was 7 months and 8 patients lived over two years, one patient is still alive (65 + months). The benefit of combined chemotherapy in non-small cell bronchogenic carcinoma remains minimal.
对100例转移性或复发性非小细胞支气管癌患者进行了一项对照临床试验，以测试两种不同的化疗方案（阿霉素+环磷酰胺+长春新碱与洛莫司汀+长春新碱）。治疗组在生存率或反应方面没有显著差异。只有4例患者部分缓解，没有完全缓解者。中位生存期为7个月，8例患者存活超过两年，1例患者仍然存活（65个多月）。联合化疗对非小细胞支气管癌的益处仍然微乎其微。
